These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15074858)

  • 1. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
    Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ; Menzies-Gow NJ; Mair TS
    Equine Vet J; 2014 Mar; 46(2):249-51. PubMed ID: 23663105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between hyperinsulinaemia and laminitis severity at the time of pituitary pars intermedia dysfunction diagnosis.
    Tadros EM; Fowlie JG; Refsal KR; Marteniuk J; Schott HC
    Equine Vet J; 2019 Jan; 51(1):52-56. PubMed ID: 29761574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.
    Meier AD; de Laat MA; Reiche DB; Pollitt CC; Walsh DM; McGree JM; Sillence MN
    Domest Anim Endocrinol; 2018 Apr; 63():1-9. PubMed ID: 29172109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital.
    Karikoski NP; Horn I; McGowan TW; McGowan CM
    Domest Anim Endocrinol; 2011 Oct; 41(3):111-7. PubMed ID: 21696910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.
    de Laat MA; Sillence MN; Reiche DB
    J Vet Intern Med; 2019 May; 33(3):1456-1463. PubMed ID: 30697823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of age and pituitary pars intermedia dysfunction on corneal sensitivity in horses.
    Miller C; Utter ML; Beech J
    Am J Vet Res; 2013 Jul; 74(7):1030-5. PubMed ID: 23802675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI; Duz M; Beech J; Parkin T; Durham AE
    J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY; Zylstra R; Haritou SJ
    Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age over 25 years, but not plasma adrenocorticotropic hormone con-cen-tration above the seasonally adjusted reference range is predictive for radio-graphically assessed changes of chronic laminitis in elderly horses.
    Christen G; Precht C; van der Kolk J; Fouché N; Gerber V
    Schweiz Arch Tierheilkd; 2020 Dec; 162(12):781-785. PubMed ID: 33263545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
    Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
    Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.